Neurology · Substance Use DisordersTrial Updateclinicalmid-term

Study on Dopamine Release in Cocaine Use Disorders Using PET Imaging

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/21/2026, 6:02:48 AM

Assessment confidence: 55% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

This study is significant as it explores the neurobiological mechanisms underlying cocaine addiction, which could lead to the development of more effective therapies. Insights gained may reshape treatment strategies and influence portfolio decisions in the addiction treatment sector. Regulatory context from PMDA ([YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted) supports the near-term read. Assessment grounded in 20 ranked evidence items (4 high-relevance).

Strategic Assessment

The findings could inform the development of targeted therapies for cocaine use disorders, impacting portfolio strategies in addiction treatment. The strongest clinical anchor is Characterization of Phenotypic and Genotypic Regressors for Imaging (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Substance Use Disorders, 2 regulatory and 3 competitive items passed relevance filtering for cocaine use disorder treatments.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease. Insights from this trial may enhance understanding of dopamine mechanisms in cocaine addiction, potentially influencing treatment approaches.

Regulatory Outlook

Regulatory risk is concentrated around [YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted (PMDA). Moderate corpus alignment. The study's outcomes may inform regulatory pathways for new treatment approvals, particularly if they demonstrate novel mechanisms of action for existing or new drugs.

Key Risks

Elevated medium regulatory exposure for cocaine use disorder treatments could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, the findings could lead to new therapies that capture market share in the addiction treatment space, enhancing revenue potential for companies involved in this therapeutic area.
The findings could inform the development of targeted therapies for cocaine use disorders, impacting portfolio strategies in addiction treatment.

What Would Change This Assessment

This becomes more urgent if Monitor results related to dopamine release patterns and their correlation with baseline PET data.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

[YAKKYOKUKATA]Press Release regarding international activities related to Pharmacopoeia posted
PMDAhigh relevance
Moderate corpus alignment
FDA document
View source
[PMDA]PMDA Concludes Memorandum of Understanding with the London School of Hygiene & Tropical Medicine (LSHTM) (News Release) (July 6, 2026) [222KB]
PMDAhigh relevance
Moderate corpus alignment
FDA document
View source

Characterization of Phenotypic and Genotypic Regressors for Imaging
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Daridorexant for People With Insomnia and Alcohol Use Disorder Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PET Imaging of Noradrenergic Transmission in the Brain
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Global Myofascial Treatment With Focused Shockwave for Non-Specific Low Back Pain: Randomized Control Trial.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
Resmetirom (Rezdiffra) Approved for MASH Treatment in Adults
Humanexa Signalsmedium relevance
Moderate corpus alignment

Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Adaption of a posttraumatic stress disorder intervention for patients who use stimulants and opioids in the opioid treatment programme setting.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut Proteobacteria glycine metabolism regulates neuroplasticity, motivation, and reinstatement of cocaine self-administration in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Do subjective and objective baseline sleep disturbances predict post-traumatic stress disorder treatment response? A secondary analysis of a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

cocaine use disorder treatments
addiction therapy market

Commercial impact

medium

If successful, the findings could lead to new therapies that capture market share in the addiction treatment space, enhancing revenue potential for companies involved in this therapeutic area.

Regulatory impact

medium

The study's outcomes may inform regulatory pathways for new treatment approvals, particularly if they demonstrate novel mechanisms of action for existing or new drugs.

What to watch

Monitor results related to dopamine release patterns and their correlation with baseline PET data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.